INNOVIVA, INC. Restricted Cash and Cash Equivalents, Noncurrent
INNOVIVA, INC. (INVA) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2014-12-31, per its 10-K filed 2015-02-27.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2015-02-27
- 2014-12-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2014-09-30: Restricted Cash and Cash Equivalents, Noncurrent $833.00K.
- 2014-06-30: Restricted Cash and Cash Equivalents, Noncurrent $833.00K.
- 2014-03-31: Restricted Cash and Cash Equivalents, Noncurrent $833.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-02-27 |
| 2014-09-30 | $833.00K 10-Q · filed 2014-11-04 |
| 2014-06-30 | $833.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $833.00K 10-Q · filed 2014-05-07 |
| 2013-12-31 | $833.00K 10-K · filed 2015-02-27 |
| 2013-09-30 | $833.00K 10-Q · filed 2013-11-01 |
| 2013-06-30 | $833.00K 10-Q · filed 2013-08-01 |
| 2013-03-31 | $833.00K 10-Q · filed 2013-05-01 |
| 2012-12-31 | $833.00K 10-K · filed 2014-03-03 |
| 2012-09-30 | $833.00K 10-Q · filed 2012-10-31 |
| 2012-06-30 | $833.00K 10-Q · filed 2012-08-01 |
| 2012-03-31 | $893.00K 10-Q · filed 2012-05-02 |
| 2011-12-31 | $893.00K 10-K · filed 2013-02-26 |
| 2011-09-30 | $893.00K 10-Q · filed 2011-11-02 |
| 2011-06-30 | $893.00K 10-Q · filed 2011-08-03 |
| 2010-12-31 | $893.00K 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |